Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3).
Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication following the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.
Hartnick
C J
CJ
Department of Otolaryngology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Cohen
A F
AF
Smith
R V
RV
D000328:Adult; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000209:etiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects*; D012075:Remission, Spontaneous
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3